Construction of Baicalein-Loaded Chitosan Nanoparticles for Staphylococcus aureus-Induced Lung Infection Remission.

IF 6.5 2区医学 Q1 NANOSCIENCE & NANOTECHNOLOGY

International Journal of Nanomedicine Pub Date : 2025-10-01 eCollection Date: 2025-01-01 DOI:10.2147/IJN.S534294

Jizhao Wang, Rui Zhu, Kaibo Yang, Zitong Lei, Xing Zhang, Yuchen Sun, Xiaozhi Zhang

{"title":"Construction of Baicalein-Loaded Chitosan Nanoparticles for Staphylococcus aureus-Induced Lung Infection Remission.","authors":"Jizhao Wang, Rui Zhu, Kaibo Yang, Zitong Lei, Xing Zhang, Yuchen Sun, Xiaozhi Zhang","doi":"10.2147/IJN.S534294","DOIUrl":null,"url":null,"abstract":"Purpose: In this study, we constructed baicalein (a traditional Chinese medicine)-loaded chitosan nanoparticles (a drug-delivery system) with great biocompatibility for the remission of Staphylococcus aureus-induced lung infection.Methods: The nanoparticles were prepared via a one-step reaction. Baicalein-release rates were studied via ultraviolet absorption assays. Morphology was characterized using AFM and TEM. The antibacterial mechanism of the nanoparticles was studied through ONPG, crystal violet staining, and live/dead bacterial staining assays, anti-inflammatory performance investigated via ELISA and WB assays, and in vivo anti-lung-infection capacity studied via H&E staining and ELISA kits.Results: The average size of the nanoparticles was uniform (~200 nm), and the zeta potential was about 18.5 ± 0.3 mV. The encapsulation efficiency was about 40%. The release of baicalein was >80% under different temperatures and pH. Dry nanoparticles were also stable. The minimum inhibitory concentration against S. aureus was about 15 μg/mL. The maximum tolerable dose in vivo was 300 μg/kg. The nanoparticles exhibited outstanding anti-inflammatory and anti-lung-infection performance.Conclusion: The in vitro and in vivo results demonstrate that our drug-delivery system could be an efficient platform for the remission of bacterium-induced lung infection.","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"12009-12018"},"PeriodicalIF":6.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497376/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nanomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJN.S534294","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"NANOSCIENCE & NANOTECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: In this study, we constructed baicalein (a traditional Chinese medicine)-loaded chitosan nanoparticles (a drug-delivery system) with great biocompatibility for the remission of Staphylococcus aureus-induced lung infection.

Methods: The nanoparticles were prepared via a one-step reaction. Baicalein-release rates were studied via ultraviolet absorption assays. Morphology was characterized using AFM and TEM. The antibacterial mechanism of the nanoparticles was studied through ONPG, crystal violet staining, and live/dead bacterial staining assays, anti-inflammatory performance investigated via ELISA and WB assays, and in vivo anti-lung-infection capacity studied via H&E staining and ELISA kits.

Results: The average size of the nanoparticles was uniform (~200 nm), and the zeta potential was about 18.5 ± 0.3 mV. The encapsulation efficiency was about 40%. The release of baicalein was >80% under different temperatures and pH. Dry nanoparticles were also stable. The minimum inhibitory concentration against S. aureus was about 15 μg/mL. The maximum tolerable dose in vivo was 300 μg/kg. The nanoparticles exhibited outstanding anti-inflammatory and anti-lung-infection performance.

Conclusion: The in vitro and in vivo results demonstrate that our drug-delivery system could be an efficient platform for the remission of bacterium-induced lung infection.

Abstract Image

查看原文本刊更多论文

黄芩素壳聚糖纳米颗粒的构建缓解金黄色葡萄球菌诱导的肺部感染。

目的：构建具有良好生物相容性的黄芩素负载壳聚糖纳米颗粒给药系统，用于缓解金黄色葡萄球菌引起的肺部感染。方法：采用一步法制备纳米颗粒。通过紫外吸收法研究黄芩素的释放率。采用原子力显微镜（AFM）和透射电镜（TEM）对其形貌进行表征。通过ONPG、结晶紫染色和活/死细菌染色研究纳米颗粒的抗菌机制，通过ELISA和WB检测研究其抗炎性能，通过H&E染色和ELISA试剂盒研究其体内抗肺部感染能力。结果：纳米粒子平均尺寸均匀（~200 nm）， zeta电位约为18.5±0.3 mV。包封效率约为40%。在不同温度和ph下，黄芩素的释放量为80%左右，干燥纳米颗粒也很稳定。对金黄色葡萄球菌的最低抑制浓度约为15 μg/mL。体内最大耐受剂量为300 μg/kg。纳米颗粒表现出优异的抗炎和抗肺部感染性能。结论：体外和体内实验结果表明，该给药系统可作为缓解细菌性肺部感染的有效平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Nanomedicine NANOSCIENCE & NANOTECHNOLOGY-PHARMACOLOGY & PHARMACY

CiteScore

14.40

自引率

3.80%

发文量

511

审稿时长

1.4 months

期刊介绍： The International Journal of Nanomedicine is a globally recognized journal that focuses on the applications of nanotechnology in the biomedical field. It is a peer-reviewed and open-access publication that covers diverse aspects of this rapidly evolving research area. With its strong emphasis on the clinical potential of nanoparticles in disease diagnostics, prevention, and treatment, the journal aims to showcase cutting-edge research and development in the field. Starting from now, the International Journal of Nanomedicine will not accept meta-analyses for publication.